Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end‐stage liver disease and normal serum creatinine awaiting liver transplantation
- 13 March 2014
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 28 (5) , 579-584
Abstract
Vitamin D deficiency is common among patients with end‐stage liver disease (ESLD). The primary aim of our study was to assess the prevalence of vitamin D deficiency, secondary hyperparathyroidism, and bone disease in patients with ESLD awaiting LT.Methods: We retrospectively studied 190 patients at our center. Serum total 25‐hydroxyvitamin D (25‐OH D), parathyroid hormone (PTH), calcium, and bone mineral analysis (BMA) were recorded. Standard World Health Organization (WHO) criteria were used to diagnose osteopenia/osteoporosis. Only patients with normal serum creatinine were analyzed.Results: Thirty‐two of 190 patients were excluded from the final analysis (missing serum total 25‐OH D levels in three patients and elevated serum creatinine, 29 patients). 105 of 158 (66.4%) evaluable patients had 25‐OH D levels 20 ng/mL (n = 71). There were no significant differences in mean serum PTH and corrected calcium levels among the three subgroups. Only three patients had elevated serum PTH. Patients with total 25‐OH D ≤ 10 ng/mL had higher model for end‐stage liver disease (MELD) scores vs. those with 25‐OH D > 20 ng/mL (13.3 ± 3, range 8–21, vs. 11.9 ± 3.4, range 6–29, p = 0.004). Irrespective of vitamin D status, bone disease was present in 64.6% of patients.Conclusion: Low vitamin D levels and bone disease are common among patients with ESLD awaiting LT. Despite a high prevalence of low serum total 25‐OH D, our cohort maintained normal corrected calcium levels and did not develop secondary hyperparathyroidism. We propose that free serum 25‐OH D and vitamin D‐binding protein may be necessary to accurately establish the diagnosis of vitamin D deficiency in the setting of ESLD. Additional studies are needed to further define mechanisms of bone disease in patients with ESLD.Keywords
This publication has 19 references indexed in Scilit:
- High prevalence of vitamin A deficiency and vitamin D deficiency in patients evaluated for liver transplantationLiver Transplantation, 2013
- D-livering the message: The importance of vitamin D status in chronic liver diseaseJournal of Hepatology, 2012
- Relationships between blood levels of fat soluble vitamins and disease etiology and severity in adults awaiting liver transplantationJournal of Gastroenterology and Hepatology, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- Forging Forward with 10 Burning Questions on FGF23 in Kidney DiseaseJournal of the American Society of Nephrology, 2010
- Current understanding of osteoporosis associated with liver diseaseNature Reviews Gastroenterology & Hepatology, 2009
- Vitamin D DeficiencyNew England Journal of Medicine, 2007
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- A Model to Predict Survival in Patients With End–Stage Liver DiseaseHepatology, 2001
- Metabolic bone disease of liver cirrhosis: Is it parallel to the clinical severity of cirrhosis?Journal of Gastroenterology and Hepatology, 1996